Phase 3 head-to-head results and an anticipated late-2026 FDA decision create strong news and comparison intent. This article was evidence-checked […]

Regulatory safety updates and new observational research are driving urgent patient questions about vision loss. This article was evidence-checked on […]

Evidence review date: September 6, 2026. GLP-1 microdosing has attracted substantial consumer and telehealth interest, but direct clinical-trial evidence remains […]

Wegovy HD vs. Zepbound is a more complicated comparison than simply placing two weight-loss percentages side by side. Wegovy HD […]

Hitting a GLP-1 weight loss plateau can be frustrating. A patient may have been losing weight consistently with semaglutide, tirzepatide, […]

Patients taking semaglutide, tirzepatide, or another GLP-1-based medication often ask how many days they must stop treatment before surgery. Current […]